Vizsgálati helyszín
MSK Nassau.
Uniondale, New York 11553, Egyesült ÁllamokMég nincs intézményhez kötve
- 17futó vizsgálat
- 3lezárt vizsgálat
Az itteni vizsgálatok
Miről szól a helyszín 20 vizsgálata, a regiszteri adatlapjaik szerint.
- Fázis
- 2. fázis8 vizsgálat
- 3. fázis6 vizsgálat
- 1. fázis3 vizsgálat
- 1/2. fázis3 vizsgálat
- Állapot
- Fut, nem toboroz8 vizsgálat
- Toboroz8 vizsgálat
- Lezárult2 vizsgálat
- Még nem toboroz1 vizsgálat
- Leállították1 vizsgálat
- Fő szponzor
- Pfizer14 vizsgálat
- Seagen, a wholly owned subsidiary of Pfizer5 vizsgálat
- Hoffmann-La Roche1 vizsgálat
Futó vizsgálatok
Toboroz
Symbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherapy in Adult Participants With Transformed Small Cell Lung Cancer
NCT07476287· 2. fázis· Pfizer· Forrás
Toboroz
Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer
NCT07421700· 1/2. fázis· Pfizer· Forrás
Toboroz
Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer
NCT07227415· 1/2. fázis· Pfizer· Forrás
Toboroz
A Study to Learn About the Study Medicine PF-08052667 in People With Bladder Cancer
NCT07206225· 1. fázis· Pfizer· Forrás
Toboroz
This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.
NCT07028853· 3. fázis· Pfizer· Forrás
Fut, nem toboroz
A Study to Evaluate the Efficacy and Safety of Autogene Cevumeran With Nivolumab Versus Nivolumab Alone in Participants With High-risk Muscle-invasive Urothelial Carcinoma (MIUC)
NCT06534983· 2. fázis· Hoffmann-La Roche· Forrás
Fut, nem toboroz
A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors
NCT06157892· 2. fázis· Seagen, a wholly owned subsidiary of Pfizer· Forrás
Fut, nem toboroz
A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30)
NCT06215118· 1. fázis· Pfizer· Forrás
Fut, nem toboroz
A Study to Learn About Vepdegestrant When Given With PF-07220060 to People With Advanced or Metastatic Breast Cancer.
NCT06206837· 1/2. fázis· Pfizer· Forrás
Fut, nem toboroz
A Study to Learn About a New Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People Who Have Advanced Metastatic Breast Cancer
NCT05654623· 3. fázis· Pfizer· Forrás
Fut, nem toboroz
A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors
NCT05538130· 1. fázis· Pfizer· Forrás
Toboroz
A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant
NCT05623020· 3. fázis· Pfizer· Forrás
Toboroz
A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer
NCT05253651· 3. fázis· Seagen, a wholly owned subsidiary of Pfizer· Forrás
Toboroz
A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2
NCT04879329· 2. fázis· Seagen, a wholly owned subsidiary of Pfizer· Forrás
Toboroz
A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
NCT05020236· 3. fázis· Pfizer· Forrás
Fut, nem toboroz
Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing
NCT05059522· 3. fázis· Pfizer· Forrás
Fut, nem toboroz
Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors
NCT03485209· 2. fázis· Seagen, a wholly owned subsidiary of Pfizer· Forrás
Egyszerre toboroz
Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.
Hibát jelzek